Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report

BACKGROUND: Due to the rarity of mesenchymal-epithelial transition factor (MET) fusions, the clinical efficacy of crizotinib has only been described in a few patients with MET fusions involving various fusion partners. Herein, we report the clinical response to crizotinib of a patient with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lian-Fang, Deng, Jia-Ying, Lizaso, Analyn, Lin, Jing, Sun, Si
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968612/
https://www.ncbi.nlm.nih.gov/pubmed/35434049
http://dx.doi.org/10.12998/wjcc.v10.i8.2529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968612/
https://www.ncbi.nlm.nih.gov/pubmed/35434049
http://dx.doi.org/10.12998/wjcc.v10.i8.2529

Ejemplares similares